New start for MorphoSys

Friday 30 July 2021
Country

Germany

MorphoSys AG ended the first half year poised to take over development of a new group of cancer drugs and potentially expand the indications for its first marketed product Monjuvi. The change comes as the company completes the acquisition of Constellation Pharmaceuticals Inc and advances trials for new uses of Monjuvi, its wholly-owned drug for refractory diffuse large B cell lymphoma. “We are writing the next chapter in our company’s history,” the MorphoSys chief executive Jean-Paul Kress, told investors during a briefing on 29 July.